Immunotherapy for breast cancer is finally at the doorstep: immunotherapy in breast cancer
LM De La Cruz, BJ Czerniecki - Annals of surgical oncology, 2018 - Springer
Background Although immunotherapy is making rapid inroads as a major treatment method
for melanoma, lung, bladder, and hereditary colon cancer, breast cancer (BC) remains one …
for melanoma, lung, bladder, and hereditary colon cancer, breast cancer (BC) remains one …
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients …
ABSTRACT HER2-directed therapies are less effective in patients with ERpos compared to
ERneg breast cancer, possibly reflecting bidirectional activation between HER2 and …
ERneg breast cancer, possibly reflecting bidirectional activation between HER2 and …
[HTML][HTML] T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells
P Namjoshi, L Showalter, BJ Czerniecki, GK Koski - Oncotarget, 2019 - ncbi.nlm.nih.gov
A recent neoadjuvant vaccine trial for early breast cancer induced strong Th1 immunity
against the HER-2 oncodriver, complete pathologic responses in 18% of subjects, and for …
against the HER-2 oncodriver, complete pathologic responses in 18% of subjects, and for …
Subtype-specific tumour immune microenvironment in risk of recurrence of ductal carcinoma in situ: prognostic value of HER2
J Solek, J Chrzanowski, A Cieslak, A Zielinska… - Biomedicines, 2022 - mdpi.com
Increasing evidence suggests that the significance of the tumour immune microenvironment
(TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but …
(TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but …
Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System
JG Wilkes, BJ Czerniecki, RLB Costa - Current Breast Cancer Reports, 2020 - Springer
Abstract Purpose of Review Breast Ductal Carcinoma in Situ (DCIS) is an increasingly
common diagnosis and already accounts for~ 20% of screen-detected breast cancers. A …
common diagnosis and already accounts for~ 20% of screen-detected breast cancers. A …